CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application
Ligand Reports Second Quarter 2020 Financial Results
Ligand’s Second Quarter Financial Results to be Reported August 3rd
Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets
Ligand CEO Issues Letter to Captisol Customers
Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases
Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics
Ligand Reports First Quarter 2020 Financial Results
Ligand’s First Quarter Financial Results to be Reported May 6th
Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call
Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies
Ligand’s Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com
Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March
Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales
